Unicycive Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Unicycive Therapeutics Stock-Based Compensation Growth & History (UNCY)
Unicycive Therapeutics's stock-based compensation was $2.6M for fiscal 2025.
View full Unicycive Therapeutics company overviewUnicycive Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.6M | $291,000 | +12.38% |
| 2024 | 2024-12-31 | $2.4M | $583,000 | +32.99% |
| 2023 | 2023-12-31 | $1.8M | $720,000 | +68.77% |
| 2022 | 2022-12-31 | $1.0M | $81,000 | +8.39% |
| 2021 | 2021-12-31 | $966,000 | $734,000 | +316.38% |
| 2020 | 2020-12-31 | $232,000 | — | — |
Unicycive Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.9M | $2.3M | +403.85% |
| Q1 2026 | 2026-03-31 | $754,000 | $191,000 | +33.93% |
| Q4 2025 | 2025-12-31 | $777,000 | $195,000 | +33.51% |
| Q3 2025 | 2025-09-30 | $730,000 | $125,000 | +20.66% |
| Q2 2025 | 2025-06-30 | $571,000 | −$70,000 | −10.92% |
| Q1 2025 | 2025-03-31 | $563,000 | $41,000 | +7.85% |
| Q4 2024 | 2024-12-31 | $582,000 | $32,000 | +5.82% |
| Q3 2024 | 2024-09-30 | $605,000 | −$324,000 | −34.88% |
| Q2 2024 | 2024-06-30 | $641,000 | $497,000 | +345.14% |
| Q1 2024 | 2024-03-31 | $522,000 | $378,000 | +262.50% |
| Q4 2023 | 2023-12-31 | $550,000 | $353,000 | +179.19% |
| Q3 2023 | 2023-09-30 | $929,000 | $663,000 | +249.25% |
| Q2 2023 | 2023-06-30 | $144,000 | −$150,000 | −51.02% |
| Q1 2023 | 2023-03-31 | $144,000 | −$146,000 | −50.34% |
| Q4 2022 | 2022-12-31 | $197,000 | −$34,000 | −14.72% |
| Q3 2022 | 2022-09-30 | $266,000 | $27,000 | +11.30% |
| Q2 2022 | 2022-06-30 | $294,000 | $0 | 0.00% |
| Q1 2022 | 2022-03-31 | $290,000 | $88,000 | +43.56% |
| Q4 2021 | 2021-12-31 | $231,000 | $161,000 | +230.00% |
| Q3 2021 | 2021-09-30 | $239,000 | $168,000 | +236.62% |
| Q2 2021 | 2021-06-30 | $294,000 | $234,000 | +390.00% |
| Q1 2021 | 2021-03-31 | $202,000 | $171,000 | +551.61% |
| Q4 2020 | 2020-12-31 | $70,000 | — | — |
| Q3 2020 | 2020-09-30 | $71,000 | — | — |
| Q2 2020 | 2020-06-30 | $60,000 | — | — |
| Q1 2020 | 2020-03-31 | $31,000 | — | — |
Unicycive Therapeutics stock-based compensation trends
Over the last five fiscal years, Unicycive Therapeutics's stock-based compensation increased from $232,000 to $2.6M, a change of $2.4M. The latest reported quarter, Q2 2026, shows $2.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Unicycive Therapeutics source filings ↗